A Novel Interleukin-11 Receptor Antibody, LASN01 Is Well Tolerated and Demonstrates Target Engagement in Phase 1

Novel treatment options for pulmonary fibrosis

Chair(s): Elisabetta Renzoni, Julien Guiot

Session type: Oral presentation

Puneet Arora

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - A KIF15 missense variant is associated with a distinct prognostic clinical phenotype in idiopathic pulmonary fibrosis

Mari Ainola

Replay

Poster

Abstract

Slides

Late Breaking Abstract - Efficacy and safety of DANAZOL for pulmonary fibrosis associated with telomere related gene mutation

Raphael Borie

Replay

Abstract

Slides

A Novel Interleukin-11 Receptor Antibody, LASN01 Is Well Tolerated and Demonstrates Target Engagement in Phase 1

Puneet Arora

Replay

Poster

Abstract

Slides

Nebulised pirfenidone in idiopathic pulmonary fibrosis (IPF): first look at FVC data

Alex West

Replay

Poster

Abstract

Slides

Post hoc pooled analyses of open-label and randomized controlled trials of senolytics dasatinib and quercetin in Idiopathic Pulmonary Fibrosis

Dean Kellogg

Replay

Poster

Abstract

Slides

Effect of BI 1015550, a preferential PDE4B inhibitor, on gene expression profiles and lung function in IPF

Luca Richeldi

Replay

Poster

Abstract

Slides

Safety and efficacy study of ACT001 in IPF and fILD patients

Ian Glaspole

Replay

Poster

Abstract

Slides

Treatment of obstructive sleep apnoea in patients with interstitial lung disease improves quality of life and survival

Katherine Myall

Replay

Poster

Abstract

Slides

A feasibility, wait-list design randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF)

Dominic Sykes

Replay

Abstract

Slides

A Randomized, Embedded, Multifactorial Adaptive Platform trial for ILD (REMAP-ILD): The conceptual design

Tejaswini Kulkarni

Replay

Poster

Abstract

Slides

Discussion and Q&A

Replay

The ERS International Congress 2023, Milan

#{title}